NCT03383055View on ClinicalTrials.gov

CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 16, 2018

Primary Completion Date

July 10, 2021

Study Completion Date

July 10, 2021

Conditions
LymphomaMultiple Myeloma
Interventions
BIOLOGICAL

CMV-MVA Triplex Vaccine

"* CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT~* TDap administered on Day 56"

Trial Locations (1)

55455

Masonic Cancer Center at University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT03383055 - CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig | Biotech Hunter | Biotech Hunter